FindTrial
Sign In

Intravenous Artesunate and Malaria

Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01805232
Acronym
IVAS
Enrollment
80
Registered
2013-03-06
Start date
2013-03-31
Completion date
2013-07-31
Last updated
2013-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Keywords

severe, Falciaparum, Malaria

Brief summary

Intravenous artesunate is egual to quinine in the treatment of severe malaria

Detailed description

Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form of fever clearance time and parasite clearance time

Interventions

DRUGartesunate

intravenous artesunate 80 mg/kg initially then after 8 hours then daily

DRUGQuinine

quinine infusion 80 mg/kg every 8 hours till the patient can take orally

Sponsors

University of Kassala, Sudan
CollaboratorOTHER
Kassala
CollaboratorUNKNOWN
Sudan
CollaboratorUNKNOWN
University of Khartoum
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

severe P.falciparum malaria-

Exclusion criteria

mixed infection Pregnant women -

Design outcomes

Primary

MeasureTime frameDescription
clearance of the parasite and fever3 daysTo compare the parasite clearance time and fever clearance time between the two groups

Countries

Sudan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026